about
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancerRepetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle.Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell cPhase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complexBone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomyClinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe.Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer.N-acetylgalactosamino dendrons as clearing agents to enhance liver targeting of model antibody-fusion protein.⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients.Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.Chemically treated activated carbon cloths for removal of volatile organic carbons from gas streams: evidence for enhanced physical adsorptionEvaluation of elemental cadmium as a marker for environmental tobacco smokeProstate cancer: Better use of bone scans in prostate cancerThe results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratificationAn N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted RadioimmunotherapyFirst-in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients
P50
Q24596266-A9EB8C46-73D6-4301-8758-591EA5A67D13Q33408380-B79B68FD-BE7F-4D50-8A6D-58A4AAB26AD6Q33789188-CACBD1BC-961D-45E9-8DFA-5AF32490C89CQ33841759-AF99B427-A3F1-4C7D-A3E4-7D2191F188ECQ33995700-6A1E840A-B097-4F45-A13E-0D28023317FFQ34368408-920E9965-218C-41DA-9C3C-7F2F65503D22Q34456470-4D1D7A71-BAD6-47C1-AAAD-44143047159BQ34681161-0AE4E19A-1DD8-4E3D-B3C7-5E5DCBDD665EQ35544056-862C229A-F697-414B-BEB0-0CF6E846C5AFQ35590083-649B55D3-71EA-4BCC-94F9-66662B760D2DQ35755818-E881EDBA-8CF4-4F2B-84CF-D4FF25073523Q36817229-45853E1B-A7C2-408D-9BA9-0BC9A89BC612Q37273125-DF2B7DA2-75B8-413A-AF6F-7B192107D4C9Q37482604-63E2F0AC-A6B3-4166-814C-423A2F945314Q37509342-31B4F73F-BCD2-40D5-AD2B-D687956D5A73Q39828822-D82E59C1-EC32-4143-98F2-E02EF160CAD2Q42721856-16E9BBFB-6E64-45C2-A2C2-72AFB68B9E19Q53165455-7E2F2F53-5BED-4B58-8151-C94B5890E43BQ82997715-B859F4CE-9574-45F6-9B55-256F7CB439AAQ83331194-935D6C15-AFE9-4B1C-87DF-2B0694489906Q85939097-1C194724-F492-4CB9-BFF3-0927DF9F36E4Q86908300-2C8FACE8-65E4-410C-9450-3900EB7653C7Q92350311-F11C0B47-A69E-46C3-A73E-2C643AD2F3ECQ94520329-90CC25CE-2D78-4A58-B72F-5BD7BC325D19
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
S M Larson
@en
S M Larson
@nl
type
label
S M Larson
@en
S M Larson
@nl
prefLabel
S M Larson
@en
S M Larson
@nl
P31
P496
0000-0002-6111-7507